| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4423185f79003e8f9b981e29323454a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate |
2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a75f78b92e3fe428f0c0160a2d1135d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdf0e7f2d99c5cee10121012ca739e18 |
| publicationDate |
2020-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-035223-B1 |
| titleOfInvention |
METHOD FOR TREATING NON-SMALL CELL LUNG CANCER |
| abstract |
The present invention relates to the use of compound 1 or a pharmaceutically acceptable salt thereof for the treatment and prevention of non-small cell lung cancer fusion positive for SLC34A2-ROS1, CD74-ROS1 or FIG-ROS1, and for inhibiting or reversing the development of cancer mediated by ROS1 kinase, where the cancer is non-small cell lung cancer fusion positive for SLC34A2-ROS1, CD74-ROS1 or FIG-ROS1. In addition, the use of a pharmaceutical composition comprising compound 1 or a pharmaceutically acceptable salt thereof and a method for inhibiting or reversing the development of cancer mediated by ROS1 kinase are described. |
| priorityDate |
2014-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |